Our team comprised of ultrasound biomedical engineers
and cytopathologists
The scientific and medical staff of Adenocyte represents a nexus of world renowned expertise in cytopathology, medical ultrasound, biomedical engineering, molecular cancer cell biology, gastroenterology, and pancreatic surgery. Our laboratories are located in Haifa and Jerusalem Israel, with clinical development and testing performed at the Technion – Israel Institute of Technology, and at North American pancreatic cancer screening centers.
Dr. Mark Rutenberg, Founder and CEO, Adenocyte
Dr. Mark Rutenberg has over thirty years of experience in the innovation, technical development, and commercialization, of advances that combine electrical engineering, computer science, pathology and oncology. His work has resulted in the early detection and prevention of thousands of carcinomas; the founding of three medical device and diagnostic companies; changing the standard of routine clinical care in gynecology, pathology, and gastroenterology, and significant returns on investment. His 20 pioneer patents in the area of diagnostic medicine have been referenced over a thousand times in subsequent patent applications. In 1990’s Mark pioneered the application of AI (neural networks) to pathology to assist in the detection of abnormal cells on routine cervical Pap smears. This technology was adopted by over 80 major US laboratories and resulted in a $1B public company. In 2000 he founded another company to apply this approach to the early detection of head and neck cancer. Used in over 350,000 patients, this technology has resulted in the early detection of thousands of unsuspected carcinomas in situ, and early treatable cancers. In 2008 Mark developed and patented Wide Area Transepithelial Sampling with three dimensional computer-assisted analysis (WATS3D) to improve the detection of Barrett’s Esophagus and esophageal dysplasia. In August 2019 WATS3D was included in the American Society for Gastrointestinal Endoscopy (ASGE) Standard of Practice guidelines for routine use in the over 5M upper endoscopies performed annually on patients with chronic heartburn Barrett’s esophagus. Dr. Rutenberg then founded Adenocyte Ltd, based in Israel to develop LINFU®, (Low Intensity Non-Focused Ultrasound) a proprietary technology designed to allow for routine, minimally invasive, screening of the pancreas for the detection of pancreatic dysplasia and early curable pancreatic cancer, the 3rd largest cause of US cancer death. Successful trials in a porcine model at the Technion - Israel Institute of Technology Medical Center in Haifa were conducted from 2018 – 2021. These results were confirmed in human clinical testing conducted in 2022-2023 using FDA cleared ultrasound technology developed for Adenocyte by GE. A nationwide clinical registry study of annual LINFU testing of elevated risk patients (first degree relatives of pancreatic cancer victims and/or one of 11 genetic markers) is scheduled to begin in February 2024. A second nationwide clinical registry study of periodic LINFU pancreatic screening of average risk patients as an addition to their routine screening colonoscopy is expected to start in 2025. Dr. Rutenberg earned a joint Ph.D. in Regulatory Biology - Cellular and Molecular Medicine from Cleveland State University and the Cleveland Clinic, an MSEE from Cleveland State University, a BA from Oberlin College, and is a graduate of the Bronx HS of Science.
Scott Korman, Chief Financial Officer, Adenocyte
• Founded (1984) Nashone, Inc., a private equity investment and advisory firm.
• Broad ranging C-suite responsibilities within various Nashone portfolio companies.
• Extensive experience leading M&A transactions and corporate turnarounds.
• Served on numerous public / private BOD.
Dr. Drore Eisen, Medical Director, Adenocyte
Dr Drore Eisen received his B.A. from Columbia University, medical degree from the Medical College of Virginia and residency training at the University of Michigan where he served as chief resident. He has co-authored two textbooks, has written many chapters in textbooks and published over 50 articles in peer-reviewed publications. Dr. Eisen played a key role in the clinical expansion of Proctor & Gamble's prescription care products developing clinical protocols and managing all national and international clinical trials. He has had extensive experience in clinical research studies serving as Co-Director of Research Associates in Cincinnati, Ohio. He has also served as a principal investigator or co-investigator in over 50 clinical trials with many large pharmaceutical companies and collaborated on cancer research projects with The National Cancer Institute. Dr. Eisen has cofounded several successful medical device companies where he also served as a Medical Director.
David Gill, Director, Adenocyte
David Gill provides strategic financing services to growth-stage companies where he can bring his operating, finance, investor relations and transaction experience to bear in accessing capital markets to fund growth and create shareholder value. Currently, Mr. Gill serves on the boards of two public companies: Y-mAbs Therapeutics (YMAB), an immuno-oncology company focused on pediatric brain cancer, and Evolus (EOLS), an aesthetics company. In addition, he serves on the boards of several private companies including as the Chairman of Healthtronics, Inc, a mobile surgical equipment company, as well as AlphaSource, a leading provider of imaging equipment parts and service. Mr. Gill’s other private company boards include RapidPulse, Inc., an ischemic stroke medical device company and Bridge to Life Ltd, a leading company in the organ transplantation market. In his most recent operating role Mr. Gill joined Endochoice (NYSE: GI) in August 2014 as CFO, executed its IPO in June 2015, and then later assumed the added roles of President and Chief Operating Officer in March 2016. EndoChoice was a 500-employee public medical device company with operations in US, Germany and Israel. Boston Scientific acquired Endochoice in November 2016, at which point Mr. Gill retired. Prior to Endochoice he was the CFO of INC Research, now known as Syneos Health, from February 2011 to August 2013 after having served as an independent board member from 2007 until late 2010. Syneos is a large, global clinical research organization (CRO) which provides outsourced pharmaceutical development services in more than 50 countries with multi-billion dollars in revenues. Earlier in his career Mr. Gill served in a variety of senior leadership roles (president, COO and CFO) for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Novoste Corporation and Dornier Medical. His biggest success was CTI, which was acquired by Siemens for $1Billion after a nine-month sales process led by Mr. Gill. While at CTI, annual sales grew from $180 million to $450 million, employees grew from 450 to 950, and shareholder value increased threefold from $350 million to $1 Billion. Mr. Gill has led the IPO’s of four companies (Endochoice in 2015, NxStage in 2005, CTI in 2002, and Interland in 2000) and has raised more than $1.3 Billion in equity and debt during his career. Mr. Gill has held a variety of executive positions with five (5) public companies and has also been involved in several corporate sale transactions as either a corporate officer or board member. Mr. Gill has significant international experience after working in Europe for a total of five years. He graduated with cum laude honors from Wake Forest University with a B.S. in Accounting and earned an MBA (with distinction) from Emory University.
Dr. Dan Adam, Chief Technology Officer, Adenocyte
Dan Adam, born in Israel, received his B.Sc. and M.Sc. (EE) and D.Sc. (BME) from the Technion in 1968, 1973 and 1977, respectively. He was at Tufts U., Boston, 1978-80, at MIT in 1980-83, teaching at Harvard-MIT HST. He joined the Technion 1983, became full Professor 2006, and Dean of the Dept. of Biomedical Engineering (2009-2012). He had a sabbatical at NIH, 1992-3. He is EAMBES founding fellow, IEEE senior member since 1964, elected to IEEE-EMBS AdCom 1999, Board of Computers in Cardiology 1990-9, Board of ISMBE since 1988, its President till 2007, and its delegate to IFMBE. He has published over 110 papers in peer-reviewed journals, 17 chapters in professional books, and has been the inventor of 12 Int. patents. He has advised over 58 MSc students, 18 PhD students, and currently leading a research group of 4-6 graduate students (2-3 PhD), 2-4 undergraduate students, 2 Scientists/Engineers. Major achievements: • Conceived and developed Echocardiography Strain Imaging, including Layer-Specific 2D Strain measurements - as a diagnostic tool of myocardial function and pathologies (together with GE Healthcare – which made it a tool in all their Echo systems). • Conceived and developed cardiac pacing by non-invasive high-intensity focused ultrasound as a tool for resuscitating cardiac arrest patients. • Conceived and developed fully automatic processing of echocardiographic clips, including Machine Learning classification of the echo views, segmenting the myocardium and classification of the Time Strain Curves to different pathologies. His research interests are ultrasound processing: Bean-forming design; Coded excitation; Ultrasound RF processing; Machine Learning based Semi-automatic classification of COVID-19 disease stages based on lung ultrasound clips; Ultrasound control of thermotherapy- monitoring of thermal-cavitational therapy; Multi-modality cardiac imaging; Ultrasound super-resolution imaging, perfusion measurements, and Quantification of neovasculature within plaques and tumours - using Contrast Agents; Targeted drug/gene delivery using ultrasound and micro-bubbles; Non-invasive thrombolysis.
Aaron Rutenberg, Director of Technical Operations, Adenocyte
Aaron has over a decade of experience in coordinating research and development projects for biomedical firms in addition to developing and managing other biomedical projects ranging from diagnostics to cytotechnology training and laboratory management.
Dor Meron, Biomedical Engineer, Adenocyte
Dor is a dedicated professional with a strong background in Biomedical Engineering. With five years of experience as an R&D engineer specializing in medical devices, he has cultivated his skills in developing automation devices that encompass hardware, software, electronics, and mechanics. His primary objective has always been to enhance efficiency and effectiveness within the medical industry. During his studies at Technion Israel Institution of Technology, Dor conducted valuable research in the field of neuroscience. With a Master's degree in Biomedical Engineering and an outstanding academic track record, he brings a solid foundation in engineering principles and a genuine passion for innovation in healthcare. Dor's exceptional expertise and astute problem-solving abilities position him as a valuable asset in driving technological advancements in the field of medical device engineering.
Zvika Palkovich, Biomedical Engineer, Adenocyte
Zvika Palkovich is a highly experienced engineer with over two decades of industry expertise. With a solid foundation in both theoretical knowledge and practical skills, he has established a successful career as a hands-on developer and team leader in the domains of signal and image processing, and system engineering, across diverse sectors including medical devices, semiconductors, defense, and automotive. Zvika holds an M.Sc. in Biomedical Engineering (2012) and a B.Sc. in Electrical Engineering (2001), both earned from the Technion. Additionally, he served as a technical officer in the Israeli Air Force (IAF), where he gained invaluable experience in radar and visual information projects.
Yoni Mozeson, Marketing Director, Adenocyte
Yoni has been involved in helping to bring biotech startups to market for more than 15 years. His strategic skills were honed at the best training ground possible - Ogilvy - the largest advertising agency in the world – where he wrote television commercials for fortune 500s. He then started his own marketing company before joining one of his biotech clients as Director of Marketing. Yoni holds a BA from Yeshiva University and an MA from Fordham.
Ellen Beth Taubman, Creative Director, Adenocyte
Ellen has directed several large and successful US, European, and Indian, medical marketing and patient communication programs since 1995.
.jpeg)
Dr Emmanuel Loeb, Veterinary Pathologist, Preclinical Studies
Dr Emmanuel Loeb is a veterinary pathologist with over twenty years of experience in the design and execution of preclinical studies, He led the preclinical testing of LINFU at the Technion since 2018.
Dr. Iyad Khamaysi, Interventional Gastroenterology, Rambam Hospital
Dr Iyad Khamaysi is director of the Advanced Endoscopy Unit and an attending physician in the Department of Gastroenterology Department at Rambam Health Care Campus. Dr. Khamaysi received his M.D. from the Tel Aviv University, Tel Aviv, Israel (1997), and is a Clinical Assistant Professor at the Ruth & Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel, since 2017. The author of dozens of publications in peer-review journals, Dr. Khamaysi also has five patents to his credit for a number of different clinical devices and medications. His research interests include clinical and experimental endoscopy, pancreatic cancer research, experimental animal models of acute pancreatitis, rheology of pancreatic cyst fluid, and medical device innovations.
Dr. Gregory B. Haber, LINFU Investigator
Professor of Medicine and Biochemistry and Molecular Pharmacology Chief of Endoscopy, NYU Langone Health Director of the Center for Advanced Therapeutics and Innovation Division of Gastroenterology, Department of Medicine, NYU Langone Health, New York, NY. Dr. Haber is one of the world’s foremost experts in clinical care and education in advanced therapeutic endoscopy. Dr. Haber has dedicated himself to the mentorship of the next generation of physicians in these techniques and technologies, having trained more than 50 advanced fellows. After receiving his medical degree from the University of Toronto, Dr. Haber completed his training in Internal Medicine and Gastroenterology. He subsequently received a Medical Research Council of Canada Grant to do postgraduate research in bile acid metabolism at the Bristol Royal Infirmary, in Bristol, England. He returned to the University of Toronto as a consultant at The Wellesley Hospital and St. Michael’s Hospital where the Advanced Endoscopy Center for the University was established. He was appointed Chief of Gastroenterology at Lenox Hill Hospital from 2004 to 2016. He took his current position at NYU Langone Health in 2016. In 2018, Dr. Haber was honored with the title of Professor of Medicine and Biochemistry and Molecular Pharmacology by NYU Langone Health. Dr. Haber has contributed over 100 scientific publications and over 200 abstracts, and has given nearly 400 presentations at educational seminars and conferences nationally and internationally. He frequently serves as a course director for educational conferences and in 2010 was the recipient of the American Society for Gastrointestinal Endoscopy’s Master of Endoscopy Award. His areas of expertise include Advanced Resection with ESD, EMR, and Full Thickness Resection, and third space intervention with POEM for achalasia, gastroparesis, and Zenker’s. He has also had a lifelong commitment to pancreatico-biliary disease with ERCP and EUS interventions, including EUS access techniques and ablation.
Dr. Martha B. Pitman, LINFU Investigator
Dr. Pitman is a Professor of Pathology at Harvard Medical School and practicing pathologist in cytopathology and gastrointestinal surgical pathology at Massachusetts General Hospital. She is past president of the Papanicolaou Society of Cytopathology and the American Society of Cytopathology. She is currently the Vice President of the International Academy of Cytology. She is the lead author of the PSC Pancreaticobiliary Terminology System for reporting pancreaticobiliary cytology as well as the new WHO Reporting System for Pancreaticobiliary Cytology. She is also on the Standing Committee (one of 5 series editors) for all WHO Reporting Systems. Her clinical research is devoted to the investigation of the early detection of pancreatic cancer, especially in association with mucinous pancreatic cysts.
Kyle Morrison, President Sonic Concepts - Adenocyte Transducer Design
With expertise in transducer design and translation to the clinic, Mr. Morrison partners with clinicians and entrepreneurs alike to effectively develop, market, brand, and sell ultrasound therapy systems for clinical adoption. Sonic Concepts licenses and manufactures its technology to clinical device companies worldwide. Kyle is a Board Member to the International Society for Therapeutic Ultrasound (ISTU) and a Faculty Lecturer to Therapy Ultrasound Winter School in Les Houches, France. He is frequently a guest speaker at international symposia such as IEEE and ASA and is a member of numerous technical committees. Mr. Morrison holds a Masters of Medical Engineering from the University of Washington.
_edited.jpg)
Dr. Kirk Wallace, Senior Scientist in Ultrasound Physics at GE Research, Niskayuna, NY.
Dr. Wallace is a physicist with 25 years of research experience in novel applications of diagnostic and therapeutic ultrasound to both clinical and preclinical medicine. He has co-authored 50+ peer-reviewed articles,12 issued patents, as well as numerous conference papers and chapters in areas of contrast enhanced ultrasound, ultrasound-mediated drug delivery, ultrasound neuromodulation, radio frequency signal processing, quantitative ultrasound, and nonlinear acoustics. Kirk earned a MA and PhD in Physics from Washington University in St Louis.